@article{075d9ea14a274cc4a5b3d45cafe99330,
title = "Avoiding a Sticky Situation: Bypassing the Mucus Barrier for Improved Local Drug Delivery",
abstract = "The efficacy of drugs administered by traditional routes is limited by numerous biological barriers that preclude reaching the intended site of action. Further, full body systemic exposure leads to dose-limiting, off-target side effects. Topical formulations may provide more efficacious drug and nucleic acid delivery for diseases and conditions affecting mucosal tissues, but the mucus protecting our epithelial surfaces is a formidable barrier. Here, we describe recent advances in mucus-penetrating approaches for drug and nucleic acid delivery to the ocular surface, the female reproductive tract, the gastrointestinal tract, and the airways.",
keywords = "drug delivery, mucoadhesive, mucoinert, mucus, mucus penetrating, nanomedicine",
author = "Zierden, {Hannah C.} and Aditya Josyula and Shapiro, {Rachel L.} and Hsueh, {Henry T.} and Justin Hanes and Ensign, {Laura M.}",
note = "Funding Information: The work was supported by the Burroughs Wellcome Preterm Birth Initiative, grant 1015020 awarded to L.M.E. the National Institutes of Health (NIH) (R01DK107806, R01EY026578, R01EY031041, R01HL136617, U19AI113127), the Robert H. Smith Family Foundation, and a departmental grant from Research to Prevent Blindness. H.C.Z. was supported by an NSF GRFP Fellowship (DGE-1746891). BioRender was used to create all figures. All authors contributed to the manuscript, assisted in revisions, read, and approved the submitted version. The mucus-penetrating particle technology is licensed and in clinical development for ocular indications by Kala Pharmaceuticals. J.H. is a founder of Kala Pharmaceuticals and serves as a consultant. L.M.E, J.H. and Johns Hopkins own company stock. Under a licensing agreement between Kala Pharmaceuticals and the Johns Hopkins University, L.M.E. J.H. and the University are entitled to royalty distributions related to the technology. These arrangements have been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. Funding Information: The work was supported by the Burroughs Wellcome Preterm Birth Initiative , grant 1015020 awarded to L.M.E., the National Institutes of Health (NIH) ( R01DK107806 , R01EY026578 , R01EY031041 , R01HL136617 , U19AI113127 ), the Robert H. Smith Family Foundation , and a departmental grant from Research to Prevent Blindness. H.C.Z. was supported by an NSF GRFP Fellowship ( DGE-1746891 ). BioRender was used to create all figures. All authors contributed to the manuscript, assisted in revisions, read, and approved the submitted version. Publisher Copyright: {\textcopyright} 2020 Elsevier Ltd",
year = "2021",
doi = "10.1016/j.molmed.2020.12.001",
language = "English (US)",
journal = "Trends in Molecular Medicine",
issn = "1471-4914",
publisher = "Elsevier Limited",
}